news
METIS meets primary endpoint
The phase 3 METIS clinical trial demonstrated a statistically significant improvement in time to intracranial progression for patients treated with Tumor Treating Fields therapy and supportive care compared to supportive care alone in the treatment of patients with brain metastases from non-small cell lung cancer following stereotactic radiosurgery.
learn moreNovocure Italy has received the 2024 Technological Innovation in Healthcare Award from the Italian Association of Clinical Engineers (#aiic). Tumor Treating Fields (TTFields) therapy was recognized as an innovative therapy for the treatment of solid tumors. #patientforward
May is Brain Tumor Awareness Month. Patients and families impacted by glioblastoma (GBM) and other cancers are at the heart of our mission. The opportunity to make a difference in their lives fuels us in our day-to-day work.
#BrainTumorAwarenessMonth #BTSM #GrayMay #GoGrayInMay
This #ClinicalTrialsDay, we honor the #TrailblazersAmongUs who work as clinical research professionals to bring innovative therapies to patients. For 10 years, Alice Chen has been one of these trailblazers on our team. Read more: https://www.novocure.com/stories/alice-chen-behind-the-scenes-of-our-clinical-trials/
A new @OncLive publication features an in-depth interview with Moshe Giladi, our Chief Science Officer, and Narasimha Kumar Karanam, Medical Science Liaison, explaining the science of Tumor Treating Fields therapy.
#TTFields #oncology #innovation #medtech
Exploring Tumor Treating Fields Therapy
THIS ARTICLE IS SPONSORED BY NOVOCURE®. This article includes expert insights from Moshe Giladi, PhD; and Narasimha ...
www.onclive.com
May is #OncologyNursingMonth, and May 12 is #InternationalNursesDay. We are grateful for the empathy and drive of nurses and nurse practitioners worldwide. Karin Gottwald is a German nurse that has joined us on our patient-forward mission. Read her story: https://www.novocure.com/stories/karin-gottwald-we-live-our-patient-forward-mission/
We have entered into a new five-year up to $400.0 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. https://www.novocure.com/novocure-secures-new-400-million-multi-tranche-non-dilutive-debt-financing-from-pharmakon/